title: Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modifications in familial hypercholesterolemia treated with lovastatin.
abstract: Fourteen patients with familial hypercholesterolemia treated with lovastatin (40 mg/day) for three months were studied to find out whether the expected changes in plasma lipids are accompanied by modifications in the lipid composition of the erythrocyte membrane and whether these in turn induce changes in the rheological behavior of the red blood cell. Our results demonstrate the efficacy of lovastatin in reducing the plasma concentration of cholesterol and LDL cholesterol. The changes observed in the plasma lipids correlate with a significant decrease in the cholesterol/phospholipid ratio of the red blood cell membrane, from 1.19 +/- 0.19 in a basal situation to 0.92 +/- 0.23 (p < 0.01) at the end of treatment. These changes in the lipid composition of the cell are statistically related to a decrease in erythrocyte aggregability and an improvement in blood filterability, which means beneficial change in the patients' hemorheological situation.
authors.affiliation: Dept Biopathol Clin, Hospital La Fe, Valencia, Spain.
authors.forename: M
authors.initials: M
authors.lastname: Martínez
authors.forename: A
authors.initials: A
authors.lastname: Vayá
authors.forename: R
authors.initials: R
authors.lastname: Martí
authors.forename: L
authors.initials: L
authors.lastname: Gil
authors.forename: I
authors.initials: I
authors.lastname: Lluch
authors.forename: R
authors.initials: R
authors.lastname: Carmena
authors.forename: J
authors.initials: J
authors.lastname: Aznar
mesh_terms: D000328:Adult; D000924:Anticholesteremic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000032:analysis; D001055:Apolipoproteins B / Q000032:analysis; D002784:Cholesterol / Q000097:blood*; D002791:Cholesterol, Dietary / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018752:Diet, Fat-Restricted; D004907:Erythrocyte Deformability; D004910:Erythrocyte Membrane / Q000737:chemistry*; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D018056:Hemorheology; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy*; D008148:Lovastatin / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D008563:Membrane Lipids / Q000097:blood*; D008875:Middle Aged; D010743:Phospholipids / Q000097:blood*
chemical_list: D000924:Anticholesteremic Agents; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D002791:Cholesterol, Dietary; D008563:Membrane Lipids; D010743:Phospholipids; D005340:Fibrinogen; D002784:Cholesterol; D008148:Lovastatin